|Articles|April 1, 2020
- Pharmaceutical Executive-04-01-2020
- Volume 40
- Issue 4
Pharmaceutical Executive, April 2020 Issue (PDF)
Click the title above to open the Pharmaceutical Executive April 2020 issue in an interactive PDF format.
Advertisement
Articles in this issue
about 6 years ago
HBA's Woman of the Year 2020: A Motivated Missionabout 6 years ago
Doubling Down on D&Iabout 6 years ago
COVID-19 Ripple Effects for Pharmaabout 6 years ago
Prescribing Patterns: How to Get Ahead of the Trendsabout 6 years ago
There’s No Easing the Price-vs.-Value Debateabout 6 years ago
Payer Perspectives on Gene Therapy Reimbursementabout 6 years ago
Covid-19 Pandemic Thrusts Biopharma R&D to Forefrontabout 6 years ago
Transforming the CIO Role to Embrace Digital Healthabout 6 years ago
Country Report: The Czech RepublicAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
Beyond JAK Inhibitors: Biologics Signal a New Era in Alopecia Areata
2
Pharma M&A Roundup: Incyte to Acquire Vega Therapeutics, Galmed Pharmaceuticals to Acquire Colospan, Johnson & Johnson Acquires Firefly Bio
3
Chai Discovery Enters License Agreement with Pfizer to Accelerate Drug Discovery with AI
4
Roche Enters $2.3 Billion Global Collaboration with Nurix Therapeutics to Co-Develop and Co-Commercialize Bexobrutideg
5